Group 1 - The innovative drug sector remains active, with companies such as Wanbangde (002082) and Hasanlian (002900) seeing significant market activity in the afternoon session [1] - Other companies like Lizhu Group (000513), Jiankangyuan (600380), and Jinshiyao (300434) are also experiencing upward movement in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating potential investor interest and market dynamics [1]

证券代码：002900 证券简称：哈三联 公告编号：2025-040 哈尔滨三联药业股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）因业务经营拓展的需求， 增加"食品用塑料包装容器工具制品生产"的经营范围。同时，根据《公司法》 等有关规定，公司对《公司章程》相关条款进行修订。公司分别于 2025 年 6 月 一次临时股东大会，审议通过了《关于变更公司经营范围及修订 <公司章程> 的 议案》。上述具体内容详见公司在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 法定代表人：秦剑飞 注册资本：人民币 316,357,550 元 成立时间：1996 年 06 月 21 日 经营范围： 许可项目：药品生产；药品批发；药品零售；药品委托生产；药品进出口； 化妆品生产；食品生产；饮料生产；食品销售；食品互联网销售；保健食品生产； 第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营；消毒剂生产 （不含危险化学品）；消毒器械生产；消毒器械销售；卫生用品和一次性使用 ...

哈尔滨三联药业股份有限公司（以下简称"公司"）因业务经营拓展的需求， 增加"食品用塑料包装容器工具制品生产"的经营范围。同时，根据《公司法》 等有关规定，公司对《公司章程》相关条款进行修订。公司分别于 2025 年 6 月 25 日召开的第四届董事会第二十二次会议及 2025 年 7 月 11 日召开的 2025 年第 一次临时股东大会，审议通过了《关于变更公司经营范围及修订<公司章程>的 议案》。上述具体内容详见公司在中国证监会指定信息披露网站巨潮资讯网 （www.cninfo.com.cn）披露的相关公告。 证券代码：002900 证券简称：哈三联 公告编号：2025-040 哈尔滨三联药业股份有限公司 关于完成经营范围变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 经营范围： 许可项目：药品生产；药品批发；药品零售；药品委托生产；药品进出口； 化妆品生产；食品生产；饮料生产；食品销售；食品互联网销售；保健食品生产； 第二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营；消毒剂生产 （不含危险化学品）；消毒器械生产；消毒 ...

创新药概念股集体调整， 塞力医疗、 联环药业跌停， 常山药业、 哈三联、 润都股份、 泓博医药、 北 陆药业、 昂利康、 舒泰神等跌超5%。 ...

Group 1 - New Yi Sheng expects a net profit increase of 327.68%-385.47% for the first half of 2025, reaching between 37 billion to 42 billion yuan, driven by growth in AI-related computing power demand and product structure optimization [2][4] - Xinghui Entertainment plans to sell 99.66% of its stake in the Spanish club Espanyol for 1.3 billion euros, with half of the payment in cash and the other half in shares [3] - *ST Yushun intends to acquire 100% of three companies for a total of 33.5 billion yuan, aiming to diversify its business into data center infrastructure services and related products [4] Group 2 - Salted Fish plans to reduce its shareholding by up to 2.04%, with a major shareholder intending to sell 5,455,572 shares [5] - Lian Microelectronics expects a net loss of approximately 1.21 billion yuan for the first half of 2025 [6] - Meinian Health anticipates a net loss of 1.92 billion to 2.36 billion yuan for the first half of 2025, with revenue expected to decline by 0.12%-5.83% [7] Group 3 - Chengdi Xiangjiang forecasts a net profit of 28 million to 42 million yuan for the first half of 2025, marking a turnaround from a loss of 69.29 million yuan in the previous year [8] - Jinpu Titanium plans to acquire 100% of Nanjing Lide Oriental Rubber and Plastic Technology Co., Ltd., with stock resuming trading after the announcement [9] - Bohai Leasing expects a net loss of 1.8 billion to 2.4 billion yuan for the first half of 2025 due to goodwill impairment from a subsidiary's asset sale [10] Group 4 - Foton Motor anticipates a net profit increase of approximately 87.5% for the first half of 2025, reaching about 777 million yuan [11] - Shenwan Hongyuan expects a net profit growth of 92.66%-111.46% for the first half of 2025, estimating profits between 4.1 billion to 4.5 billion yuan [12] - Ganfeng Lithium predicts a net loss of 5.5 billion to 3 billion yuan for the first half of 2025, an improvement from a loss of 7.6 billion yuan in the previous year [13] Group 5 - Suzhou Planning intends to acquire 100% of Beijing Dongjin Aviation Technology Co., Ltd., with stock resuming trading after the announcement [14] - Xiangyang Bearing expects a net loss of approximately 13 million yuan for the first half of 2025, slightly worse than the previous year's loss [15] - Tianqi Lithium forecasts a net profit of 0 to 1.55 billion yuan for the first half of 2025, a significant improvement from a loss of 5.2 billion yuan in the previous year [16] Group 6 - Shandong Gold anticipates a net profit increase of 84.3%-120.5% for the first half of 2025, estimating profits between 2.55 billion to 3.05 billion yuan [17] - Yunnan Geology expects a net profit of 16 million to 23 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [18] - Four-dimensional Map expects a net loss of 319 million to 268 million yuan for the first half of 2025, with revenue growth of 3.07%-14.30% [19] Group 7 - Tangrenshen anticipates a net loss of 54 million to 69 million yuan for the first half of 2025, a significant decline from the previous year's profit [20] - Changbai Mountain expects a net loss of 2.58 million to 1.58 million yuan for the first half of 2025, with revenue decreasing by approximately 7.48% [21] - Jiu Gui Jiu predicts a net profit of 8 million to 12 million yuan for the first half of 2025, a decline of 90.08%-93.39% compared to the previous year [22] Group 8 - Hengsheng Electronics expects a net profit increase of 740.95% for the first half of 2025, estimating profits around 251 million yuan [23] - Qixia Construction anticipates a net profit of 5.5 million to 8 million yuan for the first half of 2025, driven by increased project completions [24] - Poly Development expects a net profit decrease of 63.15% for the first half of 2025, estimating profits around 27.35 billion yuan [25] Group 9 - Anyuan Coal anticipates a net loss of 259 million to 310 million yuan for the first half of 2025, worsening from the previous year's loss [26] - Zhonghua Equipment plans to acquire 100% of Yiyang Rubber Machine and Beihua Machine, with stock suspension expected for no more than 10 trading days [27] - Bayi Steel expects a net loss of 650 million to 700 million yuan for the first half of 2025, primarily due to weak market conditions [28] Group 10 - Yuegui Co. anticipates a net profit increase of 58.67%-77.12% for the first half of 2025, estimating profits between 215 million to 240 million yuan [29] - Dalian Friendship expects a net loss of 38 million to 30 million yuan for the first half of 2025, with revenue impacted by tax-related issues [30] - Hangfa Power expects a net profit decrease of 84.53%-86.55% for the first half of 2025, estimating profits around 80 million to 92 million yuan [31] Group 11 - Dongfang Zirconium anticipates a net profit increase of 141.77%-156.80% for the first half of 2025, estimating profits between 25 million to 34 million yuan [32] - Hangzhou Steel expects a net profit decrease of 2% from a major shareholder's planned reduction [33] - Jingao Technology predicts a net loss of 2.5 billion to 3 billion yuan for the first half of 2025, worsening from the previous year's loss [34] Group 12 - Shanshan Co. expects a net profit increase of 810.41%-1265.61% for the first half of 2025, estimating profits between 160 million to 240 million yuan [35] - Guocheng Mining anticipates a net profit increase of 1046.75%-1174.69% for the first half of 2025, estimating profits between 493 million to 548 million yuan [36] - Jindi Group expects a net loss of 3.4 billion to 4.2 billion yuan for the first half of 2025, with significant declines in revenue [37] Group 13 - Founder Securities anticipates a net profit increase of 70%-80% for the first half of 2025, estimating profits between 22.96 billion to 24.32 billion yuan [38] - Hasi Lian expects a net loss of 98 million to 80 million yuan for the first half of 2025, a significant decline from the previous year [39] - Lanhua Ketech expects a net profit decrease of 89.12%-92.75% for the first half of 2025, estimating profits between 40 million to 60 million yuan [40] Group 14 - Shanxi Securities anticipates a net profit increase of 58.17%-70.72% for the first half of 2025, estimating profits between 5.04 billion to 5.44 billion yuan [41] - Xinda Real Estate expects a net loss of 3.5 billion to 3.9 billion yuan for the first half of 2025, with significant declines in revenue [42] - Xiangcai Co. anticipates a net profit increase of 63.64%-118.19% for the first half of 2025, estimating profits between 12 million to 16 million yuan [43] Group 15 - Longi Green Energy expects a net loss of 2.4 billion to 2.8 billion yuan for the first half of 2025, despite an increase in sales volume [44] - Wentai Technology anticipates a net profit increase of 178%-317% for the first half of 2025, estimating profits between 390 million to 585 million yuan [45] - Ruida Futures expects a net profit increase of 50.56%-83.15% for the first half of 2025, estimating profits between 206 million to 251 million yuan [46] Group 16 - Debang Co. anticipates a net profit decrease of 84.26%-87.86% for the first half of 2025, estimating profits between 40 million to 52 million yuan [47] - Jin Yi Culture expects a net loss of 20 million to 32 million yuan for the first half of 2025, a significant decline from the previous year [48] - Hongdian Film expects a net profit increase of 103.55%-160.09% for the first half of 2025, estimating profits between 180 million to 230 million yuan [49] Group 17 - Qiaqia Food anticipates a net profit decrease of 71.05%-76.25% for the first half of 2025, estimating profits between 80 million to 97.5 million yuan [50] - Guotai Haitong expects a net profit increase of 205%-218% for the first half of 2025, estimating profits between 15.283 billion to 15.957 billion yuan [51] - Xining Special Steel expects a net loss of approximately 234 million yuan for the first half of 2025, with revenue impacted by low steel prices [52]

[Harbin Sanlian Pharmaceutical Co., Ltd. 2025 H1 Earnings Forecast](index=1&type=section&id=%E5%93%88%E5%B0%94%E6%BB%A8%E4%B8%89%E8%81%94%E8%8D%AF%E4%B8%9A%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [H1 2025 Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company anticipates a significant year-over-year decline and a net loss for the first half of 2025 H1 2025 Performance Forecast | Item | Current Period (H1 2025) | Prior Year Period | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | Loss: RMB 98.00 million - 80.00 million | Profit: RMB 26.27 million | | YoY Change | Decline: 473.03% - 404.52% | - | | **Net Profit Excl. Non-recurring Items** | Loss: RMB 95.00 million - 77.00 million | Profit: RMB 21.13 million | | YoY Change | Decline: 549.50% - 464.33% | - | | **Basic Earnings Per Share (EPS)** | Loss: RMB 0.30/share - 0.24/share | Profit: RMB 0.08/share | [Communication with the Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) The company clarifies that the financial data in this earnings forecast has not been audited by an accounting firm - The financial data in this earnings forecast **has not been audited** by an accounting firm[4](index=4&type=chunk) [Explanation of Performance Fluctuation](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The shift from profit to loss is driven by lower product prices, increased depreciation, and inventory provisions [Decline in Sales Prices](index=1&type=section&id=3.1%20%E9%94%80%E5%94%AE%E4%BB%B7%E6%A0%BC%E4%B8%8B%E9%99%8D) Product selling prices fell due to national procurement policies and market competition, reducing revenue and gross profit - Product sales prices declined due to national drug procurement policies and intensified market competition[6](index=6&type=chunk) H1 2025 Forecasted Impact of Price Decline | Metric | H1 2025 Forecast | YoY Change | | :--- | :--- | :--- | | Revenue | RMB 413 million | Decrease of RMB 110 million | | Gross Profit | - | Decrease of RMB 107 million | [Operating Costs and Period Expenses](index=2&type=section&id=3.2%20%E8%90%A5%E4%B8%9A%E6%88%90%E6%9C%AC%E5%8F%8A%E6%9C%9F%E9%97%B4%E8%B4%B9%E7%94%A8) Depreciation and financial expenses increased, while selling and R&D expenses decreased - Operating costs remained relatively stable, but **depreciation expenses increased significantly by over RMB 14 million** YoY due to the capitalization of construction projects[7](index=7&type=chunk) - Overall period expenses decreased, with a combined **reduction of over RMB 27 million in selling and R&D expenses**, though financial expenses rose by over RMB 12 million[7](index=7&type=chunk) [Provision for Inventory Impairment](index=2&type=section&id=3.3%20%E8%AE%A1%E6%8F%90%E5%AD%98%E8%B4%A7%E5%87%8F%E5%80%BC%E5%87%86%E5%A4%87) An inventory impairment provision of approximately RMB 11 million is expected for H1 2025 due to lower product selling prices - An **inventory impairment provision of approximately RMB 11 million** is expected for H1 2025 due to declining sales prices[7](index=7&type=chunk) [Other Relevant Information](index=2&type=section&id=%E5%9B%9B%E3%80%81%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company states this forecast is a preliminary estimate and advises investors to refer to the final H1 2025 report - This earnings forecast is a preliminary estimate by the finance department; **final data will be in the official H1 report**[8](index=8&type=chunk)

哈三联（002900）公告，2025年1月1日至2025年6月30日，预计归属于上市公司股东的净利润亏损9800 万元-8000万元，同比下降473.03%-404.52%；扣除非经常性损益后的净利润亏损9500万元–7700万元， 同比下降549.50%-464.33%；基本每股收益亏损0.3元/股–0.24元/股。公司2025年半年度收入预计4.13亿 元，毛利下降1.07亿元。 ...

证券代码：002900 证券简称：哈三联 公告编号：2025-038 哈尔滨三联药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案或修改议案的情况；本次股东大会上无新提议 案提交表决； 2、本次股东大会不涉及变更前次股东大会决议的情况； 3、本次股东大会因涉及审议影响中小投资者利益的重大事项，公司将对中小 投资者表决情况进行单独计票。中小投资者是指以下股东以外的其他股东： （1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东。 一、会议召开情况 1、会议召开时间： （1）现场会议召开时间：2025 年 7 月 11 日（周五）16:00； （2）网络投票时间： 通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 7 月 11 日 9:15-9:25，9:30-11:30，13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 7 月 11 日 9:15-15:00 期间任意时间。 ...

北京市中伦律师事务所（以下简称"本所"）作为哈尔滨三联药业股份有限 公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席公司2025 年第一次临时股东大会（以下简称"本次股东大会"）。本所律师根据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）》《上市公司股东会规则》等相关法律、法规、规范性 文件及《哈尔滨三联药业股份有限公司章程》（以下简称"《公司章程》"）的 规定，对本次股东大会进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 法律意见书 北京市中伦律师事务所 关于哈尔滨三联药业股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：哈尔滨三联药业股份有限公司 即其已提供了本所律师认为 ...

Market Overview - The Shanghai Composite Index rose by 0.70% on July 8, with 29 out of the 31 sectors in the Shenwan classification experiencing gains, led by the communication and power equipment sectors, which increased by 2.89% and 2.30% respectively [1] - The pharmaceutical and biological industry saw a modest increase of 0.31% [1] - The sectors that declined included public utilities and banking, with decreases of 0.37% and 0.24% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets was 15.45 billion yuan, with 14 sectors experiencing net inflows [1] - The electronics sector had the highest net inflow, totaling 7.437 billion yuan, and it rose by 2.27% [1] - The power equipment sector followed with a net inflow of 3.678 billion yuan and a daily increase of 2.30% [1] - Conversely, 17 sectors experienced net outflows, with public utilities leading at a net outflow of 2.297 billion yuan, followed by the pharmaceutical and biological sector with a net outflow of 2.285 billion yuan [1] Pharmaceutical and Biological Sector Performance - Within the pharmaceutical and biological sector, 474 stocks were tracked, with 337 stocks rising and 123 stocks falling [2] - The top gainers included Zhaoyan New Drug, which saw a net inflow of 263 million yuan and a price increase of 8.27%, followed by Ha Sanlian and Mindray Medical with net inflows of 232 million yuan and 139 million yuan respectively [2] - The sector also had 10 stocks with net outflows exceeding 100 million yuan, with Changshan Pharmaceutical leading at a net outflow of 783 million yuan, followed by Yong'an Pharmaceutical and Hanyu Pharmaceutical with outflows of 236 million yuan and 208 million yuan respectively [4] Top Gainers in Pharmaceutical Sector - The top gainers in the pharmaceutical sector included: - Zhaoyan New Drug: +8.27%, turnover rate 9.51%, net inflow 262.56 million yuan - Ha Sanlian: +10.00%, turnover rate 15.14%, net inflow 232.27 million yuan - Mindray Medical: +0.43%, turnover rate 0.44%, net inflow 138.84 million yuan [2] Top Losers in Pharmaceutical Sector - The top losers in the pharmaceutical sector included: - Changshan Pharmaceutical: -12.80%, turnover rate 8.90%, net outflow -783.11 million yuan - Yong'an Pharmaceutical: -5.88%, turnover rate 20.93%, net outflow -236.84 million yuan - Hanyu Pharmaceutical: -2.33%, turnover rate 20.52%, net outflow -207.84 million yuan [4]